Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The M&M Study
NCT03844386Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2019
- Primary completion
- Nov 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MVA.tHIVconsv3 and MVA.tHIVconsv4 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) at 28 days. Started Apr 2019; status: completed.
02
Drugs
MVA.tHIVconsv3MVA.tHIVconsv4
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03844386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844386.